Ursula A. Matulonis, MD, on Current Therapies vs Novel Antibody-Drug Conjugates

Posted: Tuesday, July 30, 2019

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, compares currently available therapies for patients with ovarian cancer with novel antibody-drug conjugates such as XMT-1536 or mirvetuximab soravtansine.